A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Vatelizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Sanofi
- 02 May 2016 The time frame of the primary endpoint (participants with Adverse Events) has changed from 62 to 68 weeks
- 20 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 16 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2016 to 1 May 2016.